OLD National Bancorp IN Has $1.35 Million Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD)

OLD National Bancorp IN lowered its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 30.8% in the first quarter, HoldingsChannel reports. The firm owned 12,030 shares of the biopharmaceutical company’s stock after selling 5,365 shares during the period. OLD National Bancorp IN’s holdings in Gilead Sciences were worth $1,348,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently bought and sold shares of the business. SOA Wealth Advisors LLC. raised its stake in Gilead Sciences by 32.3% in the 1st quarter. SOA Wealth Advisors LLC. now owns 1,258 shares of the biopharmaceutical company’s stock valued at $141,000 after acquiring an additional 307 shares during the period. Miracle Mile Advisors LLC boosted its position in Gilead Sciences by 21.4% during the first quarter. Miracle Mile Advisors LLC now owns 7,976 shares of the biopharmaceutical company’s stock worth $894,000 after purchasing an additional 1,407 shares during the period. RDA Financial Network acquired a new position in shares of Gilead Sciences in the first quarter valued at $227,000. Revolve Wealth Partners LLC raised its position in shares of Gilead Sciences by 6.0% in the first quarter. Revolve Wealth Partners LLC now owns 3,487 shares of the biopharmaceutical company’s stock valued at $391,000 after purchasing an additional 196 shares during the period. Finally, Charter Oak Capital Management LLC acquired a new stake in shares of Gilead Sciences during the 1st quarter worth about $216,000. Institutional investors and hedge funds own 83.67% of the company’s stock.

Analyst Ratings Changes

GILD has been the subject of several research analyst reports. Bank of America lifted their target price on shares of Gilead Sciences from $116.00 to $126.00 and gave the stock a “buy” rating in a report on Wednesday, March 5th. Cantor Fitzgerald initiated coverage on Gilead Sciences in a report on Tuesday, April 22nd. They set an “overweight” rating and a $125.00 price objective for the company. Morgan Stanley increased their target price on Gilead Sciences from $130.00 to $135.00 and gave the stock an “overweight” rating in a research note on Friday, April 25th. JPMorgan Chase & Co. lifted their price target on Gilead Sciences from $120.00 to $130.00 and gave the stock an “overweight” rating in a report on Thursday, March 27th. Finally, BMO Capital Markets upped their price objective on Gilead Sciences from $110.00 to $115.00 and gave the company an “outperform” rating in a report on Wednesday, February 12th. Nine equities research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and three have issued a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $110.55.

Insider Buying and Selling at Gilead Sciences

In related news, insider Johanna Mercier sold 28,000 shares of the firm’s stock in a transaction that occurred on Thursday, May 22nd. The shares were sold at an average price of $107.52, for a total value of $3,010,560.00. Following the completion of the transaction, the insider now owns 121,152 shares in the company, valued at $13,026,263.04. This trade represents a 18.77% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Daniel Patrick O’day sold 10,000 shares of the business’s stock in a transaction that occurred on Friday, May 30th. The stock was sold at an average price of $110.42, for a total transaction of $1,104,200.00. Following the sale, the chief executive officer now directly owns 620,268 shares in the company, valued at $68,489,992.56. The trade was a 1.59% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 43,000 shares of company stock worth $4,630,310 over the last 90 days. Insiders own 0.27% of the company’s stock.

Gilead Sciences Stock Performance

Shares of Gilead Sciences stock opened at $113.00 on Tuesday. The company has a current ratio of 1.50, a quick ratio of 1.20 and a debt-to-equity ratio of 1.24. The company has a market cap of $140.56 billion, a PE ratio of 305.41, a price-to-earnings-growth ratio of 0.71 and a beta of 0.29. The company has a 50 day moving average of $105.41 and a 200-day moving average of $101.80. Gilead Sciences, Inc. has a 1-year low of $62.69 and a 1-year high of $119.96.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.81 EPS for the quarter, beating the consensus estimate of $1.77 by $0.04. The business had revenue of $6.67 billion during the quarter, compared to the consensus estimate of $6.77 billion. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. The company’s revenue was down .3% on a year-over-year basis. During the same period in the previous year, the business earned ($1.32) earnings per share. As a group, equities research analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 27th. Investors of record on Friday, June 13th will be paid a $0.79 dividend. This represents a $3.16 annualized dividend and a yield of 2.80%. The ex-dividend date is Friday, June 13th. Gilead Sciences’s dividend payout ratio (DPR) is presently 66.53%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.